Efficacy and safety of liposomal amphotericin B for deep mycosis in patients with connective tissue disease
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
The efficacy and safety of liposomal amphotericin B (L-AMB) in the treatment of invasive fungal infections (IFIs) were retrospectively evaluated for patients with connective tissue diseases (CTDs) during treatment with immunosuppressive therapy. Subjects were 13 patients with CTDs complicated by IFI, on the basis of clinical symptoms, imaging findings, and microbiological and histological examinations. All patients were treated with L-AMB. Efficacy and safety were evaluated before and after administration of L-AMB. Underlying diseases were systemic lupus erythematosus for 4 patients, rheumatoid arthritis for 3, microscopic polyangiitis for 2, adult-onset Still disease for 1, dermatomyositis for 1, and mixed connective tissue disease for 1. Eight patients were resistant to other antifungal drugs. Prednisolone was given to 11 patients and the median dose was 10 mg/day. Immunosuppressants were used for 8 patients. The median duration of administration of L-AMB was 8.5 days (range 4–38 days). In proven and probable diagnosis patients (n = 5), the treatment was effective for 3 patients and ineffective for 2 (efficacy rate 60 %). Serum 1,3-β-d-glucan antigenemia (BG) levels decreased after treatment in the 2 patients who were positive for BG. Serum Aspergillus galactomannan antigen levels decreased in 3 of 4 patients with Aspergillus infection. No patient died of IFI. Regarding potential adverse reactions, there were no significant changes in serum creatinine and potassium levels. L-AMB is effective and well-tolerated for treatment of IFI in patients with CTDs.
- Noël V, Lortholary O, Casassus P, Cohen P, Généreau T, André MH, et al. Risk factors and prognostic influence of infection in a single cohort of 87 adults with systemic lupus erythematosus. Ann Rheum Dis. 2001;60:1141–4. CrossRef
- Yoshida M. Efficacy of anti-β-glucan antibody in early diagnosis and treatment of opportunistic infections on immunosuppressive therapy in ANCA associated vasculitis. Rheumatology (Tokyo) 2004;31:75–81 (Japanese).
- Hirano T, Hashimoto H, Hirose S, Mori K. Clinical aspects of deep mycosis in patients with collagen diseases. Jpn J Med Mycol. 1993;34:311–16 (Japanese).
- Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol. 2011;39:954–8. CrossRef
- Quindós G, Carrillo-Muñoz AJ, Ruesga MT, Alonso-Vargas R, Miranda Y, Tur-Tur C, et al. In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens. Eur J Clin Microbiol Infect Dis. 2000;19:645–8. CrossRef
- Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother. 2002;49:21–30. CrossRef
- Adler-Moore J. AmBisome targeting to fungal infections. Bone Marrow Transplant. 1994;14:S3–7.
- Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327–60. CrossRef
- Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35. CrossRef
- De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21. CrossRef
- Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242–50. CrossRef
- Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48:1042–51. CrossRef
- Aikawa N, Kusachi S, Oda S, Takesue Y, Tanaka H. Clinical effects of micafungin, a novel echinocandin antifungal agent, on systemic fungal infections in surgery, emergency, and intensive-care medicine: evaluation using the AKOTT algorithm. J Infect Chemother. 2009;15:219–27. CrossRef
- Karino T, Osaki K, Kanamori K, Yahata T. Case of pulmonary cryptococcosis which developed in a patient receiving abatacept therapy for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi. 2010;48:980–4 (Japanese).
- Abe S, Wakamatsu N, Tanabe H, Mochizuki T, Yanagihara M, Ishizaki H, et al. A case of cutaneous cryptococcosis associated with rheumatoid arthritis. Nishinihon Hifuka. 2004;66:29–33 (Japanese).
- Winne L, Praet M, Brusselle G, Veys E, Mielants H. Bilateral spontaneous pneumothorax in a patient with pulmonary rheumatoid nodules, secondary infected by Aspergillus. Clin Rheumatol. 2007;26:1180–2. CrossRef
- Probst C, Pongratz G, Capellino S, Szeimies RM, Schölmerich J, Fleck M, et al. Cryptococcosis mimicking cutaneous cellulitis in a patient suffering from rheumatoid arthritis: a case report. BMC Infect Dis. 2010;10:239. CrossRef
- True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol. 2002;29:1561–3.
- van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med. 2003;29:2327–9. CrossRef
- Shimizu H, Miyashita N, Obase Y, Sugiu T, Ohue Y, Mouri K, et al. An asymptomatic case of pulmonary cryptococcosis with endobronchial polypoid lesions and bilateral infiltrative shadow. J Infect Chemother. 2008;14:315–8. CrossRef
- Romano C, Castelli A, Laurini L, Massai L. Case report. Primary cutaneous histoplasmosis in an immunosuppressed patient. Mycoses. 2000;43:151–4. CrossRef
- Wilson ML, Sewell LD, Mowad CM. Primary cutaneous Cryptococcosis during therapy with methotrexate and adalimumab. J Drugs Dermatol. 2008;7:53–4.
- Arend SM, Kuijper EJ, Allaart CF, Muller WH, Van Dissel JT. Cavitating pneumonia after treatment with infliximab and prednisone. Eur J Clin Microbiol Infect Dis. 2004;23:638–41. CrossRef
- Oda S, Fujinaga H, Takahashi K. Infectious myositis involving the piriformis in a patient with rheumatoid arthritis. Mod Rheumatol. 2006;16:260–3. CrossRef
- Thomas DW, Munuswamy P, Adu-Poku K, Holgate CS, Hickling P, Lambert A, et al. Candida albicans peritonitis in a patient with Felty’s syndrome. J Clin Pathol. 2005;58:432–3. CrossRef
- Mehta BM, Hashkes PJ, Avery R, Deal CL. A 21-year-old man with Still’s disease with fever, rash, and pancytopenia. Arthritis Care Res. 2010;62:575–9. CrossRef
- Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56–93. CrossRef
- Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44:1289–97. CrossRef
- Efficacy and safety of liposomal amphotericin B for deep mycosis in patients with connective tissue disease
Journal of Infection and Chemotherapy
Volume 19, Issue 4 , pp 691-697
- Cover Date
- Print ISSN
- Online ISSN
- Springer Japan
- Additional Links
- Liposomal amphotericin B
- Invasive fungal infection
- Connective tissue disease
- Preemptive treatment
- Industry Sectors
- Author Affiliations
- 1. Department of Internal Medicine (I), Osaka Medical College, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan